Esketamine nasal spray for major depressive disorder with acute suicidal ideation or behavior: description of treatment access, utilization, and claims-based outcomes in the United States.

Maryia Zhdanava,Amanda Teeple,Dominic Pilon,Aditi Shah,Gabrielle Caron-Lapointe,Kruti Joshi

Journal of medical economics（2023）

引用 0|浏览1

暂无评分

摘要

Nearly half of patients experience access issues with first esketamine nasal spray treatment session. All-cause HRU and healthcare costs trend lower in the 6 months after relative to 6 months before esketamine initiation.

查看译文

关键词

Major depressive disorder, treatment-resistant depression, esketamine, access to care, real-world use, treatment patterns, healthcare resource use, costs, suicidal ideation

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要